POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
Clinical trials for POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS explained in plain language.
Never miss a new study
Get alerted when new POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS trials appear
Sign up with your email to follow new studies for POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Myelofibrosis drug combo trial halted early
Disease control TerminatedThis study tested whether adding the drug parsaclisib to the standard treatment ruxolitinib could help people with myelofibrosis, a rare bone marrow cancer. It included 252 adults with an enlarged spleen and symptoms. The trial was terminated early, so final results are not avail…
Matched conditions: POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated May 17, 2026 02:38 UTC
-
Myelofibrosis drug combo trial halted midway
Disease control TerminatedThis study tested whether adding the experimental drug parsaclisib to the standard drug ruxolitinib could help people with myelofibrosis whose spleens were still enlarged and symptoms remained despite ruxolitinib alone. The trial enrolled 177 adults and compared the combination a…
Matched conditions: POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated May 14, 2026 12:06 UTC